Aug
2026
COEX, Seoul, Korea
Visit us
stand Q23
MFC Co.,Ltd.
Exhibitor at CPHI Korea 2026
About Us
Categories
-
Country/Region:Korea, Republic Of
-
On CPHI since:2022
-
Certificates:3
-
Employees:50 - 99
Company types
Primary activities
Event information
CPHI Korea 2026
-
25 Aug 2026 - 27 Aug 2026
-
COEX, Seoul, Korea
-
Visit us at stand Q23
Products Featured at CPHI Korea 2026
-
Product Synthesis of APIs
APIs: Pitavastatin Calcium Hydrate, Rosuvastatin Calcium, Donepezil, Clopidogrel Bisulfate, Sarpogrelate Hydrochloride, Erdosteine, Pelubiprofen, (S)-Amlodipine Besylate 2.5 Hydrate, (S)-Pantoprazole Sodium Trihydrate
Intermediates of Statins:
MRV-1, ... -
Product TBFA
High purity target compounds in solid phase (amorphous/crystalline form) rather than oil phase.
Detailed technologies: 1) High-purity synthesis technology
2) Separation and purification technology
3...
MFC Co.,Ltd. Resources (1)
-
Video MFC Co.,Ltd
MFC Co., Ltd., established in 2008, is a manufacturer specializing in APIs and key intermediates, which GMP certified from KMFDS. MFC is continuously developing under quality management through thorough quality control and quality assurance system, and technology management that put best efforts in continuous process improvement and new technology development. MFC's direction and aim are the development of new excellent new APIs and intermediates, CMO/CDMO business in accordance with customer requirements, and Incrementally Modified Drugs (IMD) & New Chemical Entity (NCE) using specialized technologies to go forward as a global pharmaceutical company.